GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Dividend Payout Ratio

MGNX (Macrogenics) Dividend Payout Ratio : 0.00 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Macrogenics's Dividend Payout Ratio for the months ended in Mar. 2025 was 0.00.

The historical rank and industry rank for Macrogenics's Dividend Payout Ratio or its related term are showing as below:


MGNX's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.47
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-07-04), the Dividend Yield % of Macrogenics is 0.00%.

Macrogenics's Dividends per Share for the months ended in Mar. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Macrogenics Dividend Payout Ratio Historical Data

The historical data trend for Macrogenics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Dividend Payout Ratio Chart

Macrogenics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Macrogenics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Macrogenics's Dividend Payout Ratio

For the Biotechnology subindustry, Macrogenics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's Dividend Payout Ratio falls into.


;
;

Macrogenics Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Macrogenics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2024 )/ EPS without NRI (A: Dec. 2024 )
=0/ -1.527
=N/A

Macrogenics's Dividend Payout Ratio for the quarter that ended in Mar. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2025 )/ EPS without NRI (Q: Mar. 2025 )
=0/ -0.65
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Macrogenics (NAS:MGNX) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Macrogenics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Macrogenics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Executives
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949